The closing price of Nektar Therapeutics (NASDAQ: NKTR) was $0.90 for the day, up 1.34% from the previous closing price of $0.89. In other words, the price has increased by $+0.0119 from its previous closing price. On the day, 1467635 shares were traded.
Ratios:
Our analysis of NKTR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.14 and its Current Ratio is at 6.45. In the meantime, Its Debt-to-Equity ratio is 1.76 whereas as Long-Term Debt/Eq ratio is at 1.61.
Jefferies Upgraded its Underperform to Hold on May 10, 2023, whereas the target price for the stock was revised from $1.50 to $1.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 20 ’24 when ROBIN HOWARD W sold 20,033 shares for $0.68 per share. The transaction valued at 13,622 led to the insider holds 879,889 shares of the business.
Zalevsky Jonathan sold 9,014 shares of NKTR for $6,130 on Feb 20 ’24. The Chief R&D Officer now owns 265,025 shares after completing the transaction at $0.68 per share. On Feb 20 ’24, another insider, Wilson Mark Andrew, who serves as the Chief Legal Officer of the company, sold 7,606 shares for $0.68 each. As a result, the insider received 5,172 and left with 236,674 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 165.26M and an Enterprise Value of -20.58M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.83 while its Price-to-Book (P/B) ratio in mrq is 1.31. Its current Enterprise Value per Revenue stands at -0.23 whereas that against EBITDA is 0.08.
Stock Price History:
Over the past 52 weeks, NKTR has reached a high of $1.12, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is 0.7146, while the 200-Day Moving Average is calculated to be 0.6079.
Shares Statistics:
NKTR traded an average of 1.61M shares per day over the past three months and 1.04M shares per day over the past ten days. A total of 191.38M shares are outstanding, with a floating share count of 178.15M. Insiders hold about 2.98% of the company’s shares, while institutions hold 65.06% stake in the company. Shares short for NKTR as of Feb 29, 2024 were 2.01M with a Short Ratio of 1.24, compared to 5.8M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.09% and a Short% of Float of 2.34%.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of -$0.19 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.22, while EPS last year was -$0.73. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.15 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.65 and -$1.21 for the fiscal current year, implying an average EPS of -$0.88. EPS for the following year is -$0.71, with 4 analysts recommending between -$0.31 and -$1.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for NKTR’s current fiscal year. The highest revenue estimate was $85.33M, while the lowest revenue estimate was $22.2M, resulting in an average revenue estimate of $67.51M. In the same quarter a year ago, actual revenue was $90.12M, down -25.10% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $62.27M in the next fiscal year. The high estimate is $81.92M and the low estimate is $22.9M. The average revenue growth estimate for next year is down -7.80% from the average revenue estimate for this year.
